40p plus closing this week after Pershing Nominees Limited and DouglasBayCapital IV Fund LP went 21% to 22.66% |
35 plus now |
Shorties still trying hard. |
0r 33p..then 32p tomorrow then 30p Friday I guess. |
Closing over 35p today |
Dear Blackhorse, This type of comment is disgusting and in very poor taste. Considering investors over at gdr have lost the majority of their investment recently. But...... apparently you sold their stock 15months ago and added here, so your probably 50percent down as well, unless your lying ha ha ha "This is a bankrupt company. I have told many times . Glad I sold here 15 months ago ago & bought APH [aliance Pharma" your own words blacksdonky |
Just seen it thanks ;) |
Date on which the threshold was crossed or reached vi:10 May 2024 |
Pershing Nominees Limited and DouglasBay increasing their holdings |
So you keep saying....yawning What time you topping up today ha ha |
SP is going up , under valued stock , last year it was 100p |
Ceo departing and delayed results aren't usually a good sign. What next the cfo departing. Seems to me something not very nice is brewing here. Better to stay well clear for now imo |
Tbh it has nothing to with the stock itself or the potential investment good or bad....but his idiotic comments and continuous spamming of other boards and his constant top ups. If I had a pound for every time he added more aph shares I'd be a very rich man now. Constantly trying to entice buyers for him to trade into is unethical imo and should be pointed out. Anyone following such comments seriously should not be investing full stop. IMHO |
He called Currys right when everyone was slagging him off so even if you do not like his repetitive and wall papering posts and even if you do not like him
He can pick some right gooduns to...I think he has here to |
1gw, you're wasting your time, he's an absolute plank, just filter him like everyone else does! |
Something brewing , buyers are back |
Last chance to BUY below 40p |
 This is just in May. Give it a rest.
-----------------------------
Blackhorse23 - 14 May 2024 - 11:13:20 - 7289 of 7290 hVIVO plc - HVO
APH about to surge
Blackhorse23 - 14 May 2024 - 08:04:44 - 200 of 201 Light Science Technologies PLC: new vertical farming/agri-tech IPO - LST
Switched to APH
Blackhorse23 - 14 May 2024 - 08:04:19 - 639 of 647 Sondrel - SND
Money moved to APH
Blackhorse23 - 13 May 2024 - 10:14:08 - 24780 of 24801 ANGLE PLC - 2019 THREAD - LIQUID BIOPSY COMPANY - AGL
Money moved to APH ( alliance Pharma )
Blackhorse23 - 13 May 2024 - 10:12:29 - 9029 of 9040 British American Tobacco - BATS
Money moved to APH ( alliance Pharma )
Blackhorse23 - 13 May 2024 - 10:11:49 - 32933 of 32936 Glaxosmithkline - The recovery - GSK
Money moved to APH ( alliance Pharma )
Blackhorse23 - 13 May 2024 - 10:11:36 - 6031 of 6032 AstraZeneca - AZN
Money moved to APH ( alliance Pharma )
Blackhorse23 - 13 May 2024 - 10:11:07 - 13787 of 13802 Shield Therapeutics: poised for a US licensing deal - STX
Money moved to APH ( alliance Pharma )
Blackhorse23 - 13 May 2024 - 10:10:51 - 1610 of 1612 Respite for ARDS sufferers - FARN
Money moved to APH ( alliance Pharma )
Blackhorse23 - 10 May 2024 - 11:06:48 - 849 of 853 Plant Health Care; Using novel biological products in global markets - PHC
Money moved to APH
Blackhorse23 - 10 May 2024 - 11:06:23 - 3767 of 3830 Genedrive, A Game Changer for Point of Care Testing Market? - GDR
Money moved to APH
Blackhorse23 - 03 May 2024 - 10:55:15 - 7269 of 7290 hVIVO plc - HVO
Money moved to APH
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 03 May 2024 - 10:53:49 - 6023 of 6032 AstraZeneca - AZN
Money moving to APH
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 03 May 2024 - 10:52:38 - 21034 of 21134 FUTURA a winner for 2015 - FUM
Money moved to APH
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 03 May 2024 - 10:52:12 - 579 of 618 O B I - OBI
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 03 May 2024 - 10:51:35 - 3673 of 3830 Genedrive, A Game Changer for Point of Care Testing Market? - GDR
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 03 May 2024 - 10:50:53 - 7759 of 7889 OXB. One owner, FSH Excellent conditionwith ejector seat - OXB
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 03 May 2024 - 10:50:34 - 57646 of 57659 Avacta – Innovative and Disruptive Technologies for Global Health Markets - AVCT
AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders
-DIVIDEND +5%
-PORTFOLIO BROADENED THROUGH ACQUISITION
Blackhorse23 - 03 May 2024 - 10:49:35 - 57645 of 57659 Avacta – Innovative and Disruptive Technologies for Global Health Markets - AVCT
Yes mate , money moved to APH
Blackhorse23 - 02 May 2024 - 19:11:04 - 7744 of 7889 OXB. One owner, FSH Excellent conditionwith ejector seat - OXB
Some investors sold out here & bought APH ( alliance Pharma ) |
Potentially a minimum gain of circa 30% or more.
But WTFDWK blacky |
 Alliance Pharma plc (AIM: APH), the international healthcare group, announces its trading update for the year ended 31 December 2023 (the "Period"), ahead of the announcement of the Group's audited results in March 2024, which are anticipated to be in line with market expectations.Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations. |
CURYman is here?... |
Get out while you can. Moneys moving anywhere but here!! |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
